Condition (MeSH)
Gerstmann-Straussler-Scheinker Disease
ClinicalTrials.gov lists 2 trials for Gerstmann-Straussler-Scheinker Disease or a narrower condition beneath it. Regeneron Pharmaceuticals has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Gerstmann-Straussler-Scheinker Disease itself; the rest are tagged with a narrower condition beneath it.
When did Gerstmann-Straussler-Scheinker Disease trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gerstmann-Straussler-Scheinker Disease trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
How many Gerstmann-Straussler-Scheinker Disease trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Gerstmann-Straussler-Scheinker Disease trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 1 |
Which publications cover Gerstmann-Straussler-Scheinker Disease? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease. | Brain pathology (Zurich, Switzerland) | 2010 | Yes |
| Molecular biology of prion diseases. | Science (New York, N.Y.) | 1991 | No |
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Gerstmann-Straussler-Scheinker syndrome | Annual incidence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Gerstmann-Straussler-Scheinker syndrome | Annual incidence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Gerstmann-Straussler-Scheinker syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Gerstmann-Straussler-Scheinker syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Gerstmann-Straussler-Scheinker syndrome | 356 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Gerstmann-Straussler-Scheinker syndrome | 356 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.